SAN DIEGO, Aug. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2017.
The Company disclosed that it has finalized an Expedited Access Pathway (EAP) program submission that its regulatory advisors will now provide to the United States Food and Drug Administration (FDA). The submission requests that the Aethlon Hemopurifier® be included in the EAP program.
The Company disclosed that it has finalized an Expedited Access Pathway (EAP) program submission that its regulatory advisors will now provide to the United States Food and Drug Administration (FDA). The submission requests that the Aethlon Hemopurifier® be included in the EAP program.
